Multiple pathways can induce and maintain peripheral T cell tolerance. The goal of this study was to define the contributions of apoptosis and anergy to the maintenance of self-tolerance to a systemic Ag. Upon transfer into mice expressing OVA systemically, OVA-specific DO11 CD4+ T cells are activated transiently, cease responding, and die. Bim is the essential apoptosis-inducing trigger and apoptosis proceeds despite increased expression of Bcl-2 and Bcl-x. However, preventing apoptosis by eliminating Bim does not restore proliferation or cytokine production by DO11 cells. While Foxp3 is transiently induced, anergy is not associated with the stable development of regulatory T cells. Thus, apoptosis is dispensable for tolerance to a systemic self-Ag and cell-intrinsic anergy is sufficient to tolerize T cells.

Multiple mechanisms contribute to peripheral T cell tolerance, including functional unresponsiveness (anergy), cell death (deletion), and suppression by regulatory T cells. It is unclear whether, or how, these mechanisms interact with one another. Recent work has been devoted to defining the molecular pathways of each of these mechanisms of tolerance and the relationships between them. For instance, it is possible that anergy is a necessary prelude to cell death or the development of peripheral regulatory T cells (Treg).3 Alternatively, each mechanism may lead to independent fates of cells that encounter self-Ags. The goal of our study was to explore the roles of anergy and apoptosis in a model amenable to detailed cellular analysis.

T cell anergy is associated with an altered and attenuated response to Ag stimulation. In vivo, anergy commonly represses proliferation and cytokine production and is maintained by continuous Ag exposure (1, 2, 3, 4, 5, 6, 7). Different mechanisms of anergy have been demonstrated in various experimental systems; these include a block in TCR signaling, the activation of ubiquitin ligases, and the engagement of inhibitory receptors (5, 8). Because anergic T cells cannot produce their own IL-2 and other survival factors, anergy may lead to apoptosis.

Lymphocytes that encounter self-Ags may be deleted through two convergent apoptotic pathways. One is initiated by the engagement of death receptors such as Fas. The other is the mitochondrial pathway, triggered by a family of sensors sharing only the BH3 domain of Bcl-2, and regulated by Bcl-2 and related prosurvival proteins (9, 10). One sensor, Bim, eliminates activated T cells in response to TCR engagement and cytokine deprivation (10). What causes Bim to kill T cells remains a puzzle and may involve changes in Bim expression and phosphorylation, changes in the levels of anti-apoptotic Bcl-2 family members, and the activation of other BH3-only sensors (10, 11, 12).

Our goal was to separate apoptosis from anergy and define the contribution of each control mechanism to systemic T cell tolerance. We previously characterized the response of OVA-specific DO11.10 CD4+ T cells transferred into soluble OVA transgenic (sOVA Tg) BALB/c recipient mice, where the OVA protein is encountered as a systemic self-Ag (13). DO11 T cells divide after transfer but rapidly become anergic and are deleted, and the surviving cells are hyporesponsive when restimulated (6). These characteristics of systemic T cell tolerance have also been reported in a different system (14).

We find that if DO11 cells lack Bim they are not deleted in sOVA Tg recipients, indicating that the major pathway of deletion is the mitochondrial apoptotic pathway. However, despite surviving chronic self-Ag exposure, these T cells become anergic. By separating apoptosis and anergy we demonstrate that cell-intrinsic anergy is sufficient to preserve tolerance to a systemic Ag.

All studies were reviewed and approved by the Committee on Animal Research (University of California, San Francisco, CA). All transgenic and knockout mice were backcrossed more than eight generations to BALB/c mice purchased from Charles River Laboratories (BALB/cAnNCrl) and The Jackson Laboratory (BALB/cJ). sOVA transgenic mice (Tg(metallothionein-I-OVA)Akab) have been described (6, 13). DO11.10 TCR transgenic mice (C.Cg-Tg(DO11.10)10Dlo/J) producing CD4+ T cells specific for chicken OVA were obtained from Dr. K. Murphy (Washington University, St. Louis, MO) via The Jackson Laboratory. Thy1.1 congenic mice (CBy.PL(B6)-Thy1a/ScrJ) were provided by Dr. R. Locksley (University of California, San Francisco, CA). B6.129-Bcl2l11tm1.1Ast/J Bim−/− mice (15) were obtained from Dr. A. Strasser (University of Melbourne, Melbourne, Australia).

The following Abs were purchased from BD Biosciences unless otherwise noted: anti-B7.2 (clone GL1), anti-Bcl-2 (clone 3F11), anti-Bcl-x (clone 7B2.5, Southern Biotech), anti-BrdU (clone 3D4), anti-CD4 (clones GK1.5 and RM4-5), anti-DO11.10 TCR (clone KJ1.26, Caltag Laboratories), anti-Foxp3 (clone FJK-16s, eBioscience), anti-I-Ad (clone AMS-32.1), and anti-Thy1.1 (clone OX-7). Flow cytometry was done on a FACSCalibur device with CellQuest software (BD Biosciences). To detect Bcl-2 and Bcl-x, cells were fixed and stained overnight in Perm/Wash buffer (BD Biosciences). Foxp3 was detected using the Foxp3 staining set (eBioscience).

DO11 donor cells were prepared from lymph nodes and spleens magnetically enriched for CD4+ cells using Dynabead (Dynal-Invitrogen) or EasySep (Stem Cell Technologies) reagents. Donor cells were labeled with 1–2.5 μM CFSE (Invitrogen Life Technologies) for 10 min and suspended in PBS for i.v. adoptive transfer of 3.5–6 × 106 total DO11 cells per recipient. OVA peptide-pulsed dendritic cells were generated as described (13) and 3 × 106 I-Ad high B7.2high cells per recipient were injected subcutaneously. After adoptive transfer, peripheral lymph nodes were collected from recipient mice, rubbed through a metal screen, suspended in medium, and counted. DO11 cells were identified as staining CD4+ KJ1.26+ when analyzed by flow cytometry.

DO11 cells were purified from lymph nodes of recipient mice with a MoFlo high-speed sorter (DakoCytomation) and restimulated in vitro with OVA peptide as described (6). Cytokine production was measured by an alkaline phosphatase ELISA of the culture supernatants (BD Bioscience, Sigma-Aldrich, and Molecular Devices). Proliferation was measured by incorporation of [3H]thymidine during the final 18 h of culture.

cDNA was obtained from purified DO11 cells using TRIzol and the SuperScript III kit (Invitrogen Life Technologies) and detected using SYBR Green (Applied Biosystems) and the Opticon 2 system (Bio-Rad Laboratories). Relative gene expression was determined by the critical threshold and normalization to hypoxanthine phosphoribosyltransferase (HPRT). The following PCR primers were used: Bcl-2 (5′-AGTACC-TGAACC-GGCATC-TG/GCTGAG-CAGGGT-CTTCAG-AG-3′), Bcl-x (5′-GCTGGG-ACACTT-TTGTGG-AT/AAGAGT-GAGCCC-AGCAGA-AC-3′), and HPRT (5′-TGCCGA-GGATTT-GGAAAA-AGTG/CACAGA-GGGCCA-CAATGT-GATG-3′).

Mice were given i.p. injections of 1 mg BrdU in PBS on days 0, 1, 2, 4, and 6 beginning day 0 or 14 after DO11 cell transfer. Cells were stained for surface Ags, fixed, and frozen (protocol option 2; BD Biosciences). Thawed cells were incubated for 60 min at 37° in PBS supplemented with 10 μM HCl, 150 mM NaCl, 4.2 mM MgCl2 and 250 Kunitz units/ml DNase I (Sigma-Aldrich) to digest DNA before staining to detect BrdU.

To define the mechanisms of T cell deletion induced by a systemic self-Ag, we cotransferred DO11 wild-type (WT) Thy1.1+ and Bim−/− Thy1.2+ cells into BALB/c or sOVA Tg recipients and followed the fates of the two T cell populations. Both cell populations exhibited a naive phenotype before transfer (not shown). The DO11 WT and Bim−/− populations engrafted equally, and by day 4 they displayed similar proliferation in sOVA Tg mice as shown by CFSE profiles (Fig. 1,A). WT and Bim−/− DO11 cells were also equivalently CD69+, IL-7Rαlow, CD44high, CD62Llow, and OX-40+ on day 4 in sOVA Tg mice (not shown). However, compared with their WT counterparts, Bim−/− DO11 cells showed much less deletion in sOVA Tg mice and, over time, the ratio of the surviving populations increasingly favored Bim−/− cells (Fig. 1, B and C). In fact, the number of Bim−/− DO11 cells remained stable as long as 8 wk after transfer (not shown). We observed similar enhanced survival of Bim−/− vs WT DO11 cells when the two populations were transferred into separate sOVA Tg recipients (not shown).

FIGURE 1.

Bim deficiency reduces the deletion of T cells following encounter with systemic Ag. DO11 WT Thy1.1 and DO11 Bim−/− Thy1.2 cells were labeled with CFSE, mixed 1:1, and cotransferred into BALB/c or sOVA Tg recipients. A, CFSE profiles of DO11 cells, normalized to the global maximum. B, Number of DO11 cells in lymph nodes 4, 8, and 13 days after transfer. C, Ratio of Bim−/− to WT DO11 cells.

FIGURE 1.

Bim deficiency reduces the deletion of T cells following encounter with systemic Ag. DO11 WT Thy1.1 and DO11 Bim−/− Thy1.2 cells were labeled with CFSE, mixed 1:1, and cotransferred into BALB/c or sOVA Tg recipients. A, CFSE profiles of DO11 cells, normalized to the global maximum. B, Number of DO11 cells in lymph nodes 4, 8, and 13 days after transfer. C, Ratio of Bim−/− to WT DO11 cells.

Close modal

Death by the mitochondrial pathway may reflect the loss of prosurvival Bcl-2 family members, and failure to induce these proteins following self-Ag recognition is a basis of deletion (16, 17). To test this, we followed the expression of Bcl-2 and Bcl-x following T cell encounter with systemic self-Ag. Relative to naive controls, DO11 cells in sOVA Tg recipients expressed higher levels of Bcl-2 and Bcl-x mRNA (Fig. 2,A). Within 1 day of transfer, DO11 cells expressed more Bcl-2 and Bcl-x protein in sOVA Tg than BALB/c recipients (Fig. 2 B). Elevated Bcl-2 and Bcl-x expression was sustained through day 7, by which time most WT cells had been deleted. DO11 Bim−/− cells also expressed more Bcl-2 and Bcl-x in sOVA Tg than BALB/c recipients (not shown). Thus, Bim-dependent apoptosis in the sOVA transgenic system is not associated with a failure to express Bcl-2 or Bcl-x.

FIGURE 2.

Expression of Bcl-2 and Bcl-x in T cells following transfer into sOVA Tg recipients. A, CFSE-labeled WT DO11 cells were sorted from BALB/c or sOVA Tg recipients 1 or 4 days after transfer and processed to yield cDNA. Quantitative PCR was performed to measure mRNA levels of Bcl-2 and Bcl-x normalized to HPRT expression in the same cDNA sample. Only divided DO11 cells were isolated from the day 4 sOVA Tg mice. B, Bcl-2 and Bcl-x coexpression in DO11 WT cells was measured by flow cytometry after 1, 2, 4, and 7 days in BALB/c or sOVA Tg recipients.

FIGURE 2.

Expression of Bcl-2 and Bcl-x in T cells following transfer into sOVA Tg recipients. A, CFSE-labeled WT DO11 cells were sorted from BALB/c or sOVA Tg recipients 1 or 4 days after transfer and processed to yield cDNA. Quantitative PCR was performed to measure mRNA levels of Bcl-2 and Bcl-x normalized to HPRT expression in the same cDNA sample. Only divided DO11 cells were isolated from the day 4 sOVA Tg mice. B, Bcl-2 and Bcl-x coexpression in DO11 WT cells was measured by flow cytometry after 1, 2, 4, and 7 days in BALB/c or sOVA Tg recipients.

Close modal

It is possible that T cells surviving encounter with self-Ag also retain their functional responsiveness. To test this, we assayed the responses of DO11 T cells transferred into sOVA Tg recipients and, for comparison, into untreated BALB/c mice and BALB/c mice immunized with OVA peptide-pulsed dendritic cells. T cells were purified 5 days after transfer and restimulated in vitro. Both DO11 WT and Bim−/− cells from sOVA transgenic mice were impaired in IL-2 production, failed to make IL-4, IFN-γ, or IL-10, and proliferated no better than naive cells (Fig. 3, and data not shown).

FIGURE 3.

Bim deficiency does not prevent anergy. DO11 WT and Bim−/− cells were labeled with CFSE and transferred into BALB/c or sOVA Tg recipients. BALB/c recipients were left untreated (naive) or immunized with OVA-pulsed dendritic cells (immunized) 1 day later. On day 5, all (naive) or divided (immunized sOVA Tg) DO11 cells were sorted and restimulated in vitro. A, IL-2 production after 36 h, measured by ELISA. B and C, IL-4 (B) and IFN-γ production (C) measured after 3 days by ELISA. D, Proliferation after 4 days, measured by [3H]thymidine incorporation.

FIGURE 3.

Bim deficiency does not prevent anergy. DO11 WT and Bim−/− cells were labeled with CFSE and transferred into BALB/c or sOVA Tg recipients. BALB/c recipients were left untreated (naive) or immunized with OVA-pulsed dendritic cells (immunized) 1 day later. On day 5, all (naive) or divided (immunized sOVA Tg) DO11 cells were sorted and restimulated in vitro. A, IL-2 production after 36 h, measured by ELISA. B and C, IL-4 (B) and IFN-γ production (C) measured after 3 days by ELISA. D, Proliferation after 4 days, measured by [3H]thymidine incorporation.

Close modal

A stringent test of anergy is the proliferation of T cells in vivo after encounter with systemic Ag. We first noticed cell cycle arrest of DO11 cells in sOVA Tg recipients when comparing CFSE dilution beyond 4 days after transfer (Fig. 1,A, compare days 4 and 13). To better define cell division, Bim−/− DO11 cells were transferred into BALB/c or sOVA Tg recipients and treated with BrdU. Bim−/− DO11 cells stained BrdU+ and therefore had entered the cell cycle during week 1 but not week 3 following transfer into sOVA Tg mice (Fig. 4). Thus, the surviving T cells fail to proliferate in the presence of the systemic Ag.

FIGURE 4.

DO11 Bim−/− cells cease dividing in vivo. DO11 Bim−/− cells were transferred into BALB/c or sOVA Tg mice and recipients were treated with BrdU for the first or third week posttransfer. A, To identify dividing DO11 cells, BrdU uptake was detected by flow cytometry. B, Percentages of BrdU+ (dividing) DO11 cells. Equal labeling of endogenous CD4+KJ cells demonstrates equal availability of BrdU.

FIGURE 4.

DO11 Bim−/− cells cease dividing in vivo. DO11 Bim−/− cells were transferred into BALB/c or sOVA Tg mice and recipients were treated with BrdU for the first or third week posttransfer. A, To identify dividing DO11 cells, BrdU uptake was detected by flow cytometry. B, Percentages of BrdU+ (dividing) DO11 cells. Equal labeling of endogenous CD4+KJ cells demonstrates equal availability of BrdU.

Close modal

We also monitored the sOVA Tg recipients of Bim−/− DO11 cells up to 8 wk for signs of autoimmune disease. Anti-OVA IgG Abs were essentially undetectable (not shown). DO11 donor cells cause a rapid wasting disease and severe skin inflammation in RAG-deficient sOVA Tg recipients in which tolerance has failed (18). However, Bim-deficient DO11 cells caused neither symptom in WT sOVA Tg mice.

It is possible that the long-lived unresponsiveness of T cells in the presence of systemic Ag is related to the induction of Treg. To address this, we determined whether WT or Bim−/− DO11 cells differentiated into Foxp3-expressing Tregs after transfer into sOVA Tg mice. Naive KJ1–26+ T cells from conventional DO11 mice are 2–3% Foxp3+, presumably because of the expression of a second, self-reactive TCR (19, 20). At 4 days after transfer there is an increase in the percentage of both WT and Bim−/− DO11 cells expressing Foxp3 (Fig. 5). However, in the surviving Bim−/− population the percentage of Foxp3+ DO11 cells returned to the naive level. Foxp3 was also induced when RAG-deficient DO11 cells were transferred into sOVA Tg mice (not shown). Thus, transient expression of Foxp3 may be a feature of self-Ag recognition, but the development of stable Tregs cannot explain the long-lived unresponsiveness of T cells in the presence of the systemic Ag.

FIGURE 5.

Systemic Ag does not induce stable Foxp3+ cells. DO11 WT Thy1.1 and DO11 Bim−/− Thy1.2 cells were mixed 1:1, cotransferred into BALB/c or sOVA Tg recipients, and analyzed 4 and 14 days later by flow cytometry. A, Foxp3 expression in WT (Thy1.1+) and Bim−/− (Thy1.1) DO11 cells. The fraction of Foxp3+ cells in either WT or Bim−/− donor populations are shown. B, Number of Foxp3+ and Foxp3 DO11 cells after 4 and 14 days. One-sided error bars are shown for clarity.

FIGURE 5.

Systemic Ag does not induce stable Foxp3+ cells. DO11 WT Thy1.1 and DO11 Bim−/− Thy1.2 cells were mixed 1:1, cotransferred into BALB/c or sOVA Tg recipients, and analyzed 4 and 14 days later by flow cytometry. A, Foxp3 expression in WT (Thy1.1+) and Bim−/− (Thy1.1) DO11 cells. The fraction of Foxp3+ cells in either WT or Bim−/− donor populations are shown. B, Number of Foxp3+ and Foxp3 DO11 cells after 4 and 14 days. One-sided error bars are shown for clarity.

Close modal

T cell anergy and deletion preserve tolerance to self-Ags. In this study we show that anergy and deletion are separable mechanisms and tolerance can be maintained even if deletion is prevented. When T cells encounter systemic self-Ag in the sOVA Tg recipients, deletion of the cells depends on Bim and occurs despite increased Bcl-2 and Bcl-x. In contrast, Bim-mediated deletion by superantigen is linked to a loss of Bcl-2 (16, 17). This difference may result from different pathways of Bim activation. In sOVA Tg mice, repetitive TCR stimulation could activate Bim by qualitatively changing the protein, perhaps by mRNA splicing or phosphorylation (11), to overcome the increased expression of Bcl-2 and Bcl-x. Superantigen-mediated deletion could instead activate the Bim pathway in the same way as cytokine withdrawal, reducing the expression of Bcl-2 and relieving the inhibition of unmodified Bim (10).

Without Bim, thymic and peripheral T cells resist deletion, lymphocyte homeostasis breaks down, and class-switched autoantibodies are produced (15, 16, 21, 22, 23, 24). However, Bim is not required to prevent overt autoimmune disease because Bim−/− C57BL/6 mice do not exhibit increased mortality (24). Thus, Bim is required at the cellular level to delete self-reactive lymphocytes and maintain immune homeostasis, but Bim-mediated deletion is not necessary for immune tolerance if independent mechanisms, such as anergy or suppression by Tregs, compensate for impaired apoptosis.

Besides triggering the Bim pathway, chronic self-Ag exposure induces cell-intrinsic anergy. Repeatedly encountering Ag can desensitize T cells (1, 3, 4, 5, 7, 14, 25, 26), and DO11 cells developed a defect in calcium mobilization upon anti-CD3 Ab stimulation within 3 days of transfer into sOVA Tg mice (6). The phenotype of tolerant DO11 Bim−/− cells, namely loss of IL-2 and proliferation, failure to produce effector cytokines, and aberrant calcium response, are commonly shared characteristics of anergy in many systems (5, 25) and could be explained if E3 ubiquitin ligases maintain anergy by degrading key components of the TCR signaling pathway (8).

It is also possible that tolerance is maintained by the generation of Ag-specific Tregs. However, Foxp3 is induced only transiently in DO11 cells following transfer into sOVA Tg recipients, and stable populations of Foxp3+ T cells do not emerge. It may be that T cells encountering systemic self-Ag rapidly become anergic and fail to complete the Treg differentiation program. This hypothesis predicts that some degree of activation is a necessary prelude to peripheral Treg generation. Therefore, anergy and Treg development may be alternative fates of T cells that are exposed chronically to a self-Ag. These results indicate that differentiation into Tregs cannot explain the unresponsiveness of the surviving DO11 Bim−/− population and the absence of autoimmune pathology.

The experimental system of a single T cell population encountering a systemic Ag has allowed us to dissect the requirements for triggering different mechanisms of self-tolerance and the relative contributions of these mechanisms. We find that deletion is mediated by the Bim-dependent mitochondrial pathway of apoptosis and can be significantly reduced by the genetic elimination of Bim. However, prolonged survival alone does not lead to a failure of self-tolerance, because the cells become functionally anergic. Thus, anergy and apoptosis are separable fates of T cells that encounter self-Ag.

We thank Dr. A Strasser for Bim−/− mice. We are indebted to S. Jiang for expert cell sorting and C. Benitez for mice husbandry. We thank Dr. C. Allen for technical advice and members of the Abbas laboratory for helpful discussions.

The authors have no financial conflict of interest.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1

This work was supported by National Institutes of Health Grant PO1 AI35297.

3

Abbreviations used in this paper: Treg, regulatory T cell; sOVA Tg, soluble OVA transgenic; HPRT, hypoxanthine phosphoribosyltransferase; WT, wild type.

1
Rocha, B., C. Tanchot, H. Von Boehmer.
1993
. Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen.
J. Exp. Med.
177
:
1517
-1521.
2
Pape, K. A., R. Merica, A. Mondino, A. Khoruts, M. K. Jenkins.
1998
. Direct evidence that functionally impaired CD4+ T cells persist in vivo following induction of peripheral tolerance.
J. Immunol.
160
:
4719
-4729.
3
Tanchot, C., D. L. Barber, L. Chiodetti, R. H. Schwartz.
2001
. Adaptive tolerance of CD4+ T cells in vivo: multiple thresholds in response to a constant level of antigen presentation.
J. Immunol.
167
:
2030
-2039.
4
Bachmann, M. F., U. H. Rohrer, U. Steinhoff, K. Burki, S. Skuntz, H. Arnheiter, H. Hengartner, R. M. Zinkernagel.
1994
. T helper cell unresponsiveness: rapid induction in antigen-transgenic and reversion in non-transgenic mice.
Eur. J. Immunol.
24
:
2966
-2973.
5
Choi, S., R. H. Schwartz.
2007
. Molecular mechanisms for adaptive tolerance and other T cell anergy models.
Semin. Immunol.
19
:
140
-152.
6
Knoechel, B., J. Lohr, S. Zhu, L. Wong, D. Hu, L. Ausubel, A. K. Abbas.
2006
. Functional and molecular comparison of anergic and regulatory T lymphocytes.
J. Immunol.
176
:
6473
-6483.
7
Chen, T. C., S. P. Cobbold, P. J. Fairchild, H. Waldmann.
2004
. Generation of anergic and regulatory T cells following prolonged exposure to a harmless antigen.
J. Immunol.
172
:
5900
-5907.
8
Fathman, C. G., N. B. Lineberry.
2007
. Molecular mechanisms of CD4+ T-cell anergy.
Nat. Rev. Immunol.
7
:
599
-609.
9
Marsden, V. S., A. Strasser.
2003
. Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more.
Annu. Rev. Immunol.
21
:
71
-105.
10
Marrack, P., J. Kappler.
2004
. Control of T cell viability.
Annu. Rev. Immunol.
22
:
765
-787.
11
Strasser, A..
2005
. The role of BH3-only proteins in the immune system.
Nat. Rev. Immunol.
5
:
189
-200.
12
Willis, S. N., J. M. Adams.
2005
. Life in the balance: how BH3-only proteins induce apoptosis.
Curr. Opin. Cell Biol.
17
:
617
-625.
13
Lohr, J., B. Knoechel, E. C. Kahn, A. K. Abbas.
2004
. Role of B7 in T cell tolerance.
J. Immunol.
173
:
5028
-5035.
14
Singh, N. J., C. Chen, R. H. Schwartz.
2006
. The impact of T cell intrinsic antigen adaptation on peripheral immune tolerance.
PLoS Biol.
4
:
e340
15
Bouillet, P., D. Metcalf, D. C. Huang, D. M. Tarlinton, T. W. Kay, F. Kontgen, J. M. Adams, A. Strasser.
1999
. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity.
Science
286
:
1735
-1738.
16
Hildeman, D. A., Y. Zhu, T. C. Mitchell, P. Bouillet, A. Strasser, J. Kappler, P. Marrack.
2002
. Activated T cell death in vivo mediated by proapoptotic bcl-2 family member bim.
Immunity
16
:
759
-767.
17
Hildeman, D. A., Y. Zhu, T. C. Mitchell, J. Kappler, P. Marrack.
2002
. Molecular mechanisms of activated T cell death in vivo.
Curr. Opin. Immunol.
14
:
354
-359.
18
Knoechel, B., J. Lohr, E. Kahn, A. K. Abbas.
2005
. The link between lymphocyte deficiency and autoimmunity: roles of endogenous T and B lymphocytes in tolerance.
J. Immunol.
175
:
21
-26.
19
Itoh, M., T. Takahashi, N. Sakaguchi, Y. Kuniyasu, J. Shimizu, F. Otsuka, S. Sakaguchi.
1999
. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance.
J. Immunol.
162
:
5317
-5326.
20
Knoechel, B., J. Lohr, E. Kahn, J. A. Bluestone, A. K. Abbas.
2005
. Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen.
J. Exp. Med.
202
:
1375
-1386.
21
Bouillet, P., J. F. Purton, D. I. Godfrey, L. C. Zhang, L. Coultas, H. Puthalakath, M. Pellegrini, S. Cory, J. M. Adams, A. Strasser.
2002
. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes.
Nature
415
:
922
-926.
22
Villunger, A., V. S. Marsden, Y. Zhan, M. Erlacher, A. M. Lew, P. Bouillet, S. Berzins, D. I. Godfrey, W. R. Heath, A. Strasser.
2004
. Negative selection of semimature CD4+8HSA+ thymocytes requires the BH3-only protein Bim but is independent of death receptor signaling.
Proc. Natl. Acad. Sci. USA
101
:
7052
-7057.
23
Davey, G. M., C. Kurts, J. F. Miller, P. Bouillet, A. Strasser, A. G. Brooks, F. R. Carbone, W. R. Heath.
2002
. Peripheral deletion of autoreactive CD8 T cells by cross presentation of self-antigen occurs by a Bcl-2-inhibitable pathway mediated by Bim.
J. Exp. Med.
196
:
947
-955.
24
Erlacher, M., V. Labi, C. Manzl, G. Bock, A. Tzankov, G. Hacker, E. Michalak, A. Strasser, A. Villunger.
2006
. Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction.
J. Exp. Med.
203
:
2939
-2951.
25
Schwartz, R. H..
2003
. T cell anergy.
Annu. Rev. Immunol.
21
:
305
-334.
26
Grossman, Z., W. E. Paul.
2001
. Autoreactivity, dynamic tuning and selectivity.
Curr. Opin. Immunol.
13
:
687
-698.